Article

Lomitapide: A Medication Use Evaluation & a Formulary Perspective

2023-03-02

Abstract excerpt

<title>Abstract</title> <p><bold>Background and aims: </bold>Lomitapide is approved for lowering LDL-C in homozygous familial hypercholesterolemia, a rare genetic disorder. The evidence on its safety and efficacy from a small clinical trial requires further validation on effectiveness and safety in real-world. The aim of this study was to utilize institutional data on effectiveness and safety of lomitapide; to as...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8a5f2891-6b54-58fe-82eb-b74991d2fcac
DOI: 10.21203/rs.3.rs-2275638/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lomitapide: A Medication Use Evaluation & a Formulary PerspectiveDOI 10.21203/rs.3.rs-2275638/v1Read

Lomitapide for the treatment of hypercholesterolemia.Semantic proximity Read

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.Semantic proximity Read

Lomitapide for the management of homozygous familial hypercholesterolemia.Semantic proximity Read

Autosomal recessive hypercholesterolemia: update for 2020.Semantic proximity Read

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.Semantic proximity Read

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Semantic proximity Read

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.Semantic proximity Read

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.Semantic proximity Read

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.Semantic proximity Read

MTTP gene variants and lomitapide response in a cohort of patients with homozygous familial hypercholesterolemiaSemantic proximity Read

Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.Semantic proximity Read

Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary.Semantic proximity Read